Drug intelligence / Profile preview

Cadisurf

Development stage: Phase 3
Modality: Recombinant Proteins and Enzymes
Administration: Intratracheal

Overview

Cadisurf is an investigational goat lung surfactant extract developed for the treatment of Respiratory Distress Syndrome (RDS) in preterm neonates. It is administered intratracheally to replace deficient endogenous surfactant, thereby reducing surface tension in the alveoli and improving lung function. The drug is being evaluated in a multi-site randomized clinical trial against Survanta (beractant), a standard preparation, to compare its efficacy and safety.

Brand names: Cadisurf
Other names: goat lung surfactant extractGLSE

Beyond the preview

Go deeper on Cadisurf.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadisurf.

Explore the full profile